The board of directors of biopharmaceutical company Pfizer Inc (NYSE:PFE) declared the company's 321st consecutive dividend of USD0.36 of its common stock for the first quarter 2019, it reported on Friday.
This new dividend marks a growth of approximately 6% from the prior dividend of USD0.34 per share of its common stock.
Shareholders of record at the close of business as of 1 February 2019 will receive the dividend on 1 March 2019,
Additionally, the board of directors has launched a new USD10bn share repurchase programme,which is in addition to the USD4.9bn remaining under its current authorisation.
Bio-Rad Laboratories Names Daskal as EVP and Chief Financial Officer
Bio-Rad Received US FDA Clearance for Test to Aid in the Diagnosis of Lyme Disease
Titan Pharmaceuticals incurs lower net loss of USD9.3m for 2018
Vaxart Completes Dosing of the Lead-In Cohort in Bivalent Norovirus Vaccine Phase 1b Clinical Trial
Phio Pharmaceuticals narrows net loss to USD7.4m in 2018
Curis reports lower net loss of USD32.6m in 2018
Biotoscana Investments announces 2018 financial results
Varex to close acquisition of Direct Conversion AB in Q3 current fiscal year
Zealand Pharma announces share capital increase under collaboration with Alexion Pharmaceutical
Apollo Endosurgery posts higher net loss USD18.4m for Q4 2018
PDL BioPharma reports 2018 financial results
CTI BioPharma reports 2018 financial results
Inovio Pharmaceuticals incurs higher net loss of USD97.0m in 2018